Omalizumab in the Treatment of Hyper-IgE Syndrome: 2 Case Reports

J Investig Allergol Clin Immunol. 2020;30(3):191-192. doi: 10.18176/jiaci.0469. Epub 2019 Dec 10.

Authors

N Gomes¹, J Miranda², S Lopes¹, L Carneiro-Leão², J Torres Costa², T Baudrier¹, F Azevedo¹

Affiliations

¹ Dermatovenereology Department, Centro Hospitalar Universitário de São João, Porto, Portugal.
² Allergy and Clinical Immunology Department, Centro Hospitalar Universitário de São João, Porto, Portugal.

PMID: 31820738
DOI: 10.18176/jiaci.0469

No abstract available

Keywords: DOCK8; Eczema; Hyper-IgE syndrome; Omalizumab; STAT3.

Publication types

Case Reports

MeSH terms

Adult
Anti-Allergic Agents / therapeutic use*
Eczema
Eosinophilia
Guanine Nucleotide Exchange Factors / genetics*
Humans
Immunoglobulin E / immunology
Immunoglobulin E / metabolism*
Job Syndrome / drug therapy*
Job Syndrome / genetics
Male
Mutation / genetics*
Omalizumab / therapeutic use*
STAT3 Transcription Factor / genetics*

Substances

Anti-Allergic Agents
DOCK8 protein, human
Guanine Nucleotide Exchange Factors
STAT3 Transcription Factor
Omalizumab
Immunoglobulin E